Study summary

A daily BTK inhibitor pill shrank relapsed brain lymphoma in two-thirds of patients

PROSPECT trial (tirabrutinib) · 48 people, phase 2 · Published October 2026, Blood; FDA decision due December 18, 2026

67%response rate

What was tested

Tirabrutinib, a once-daily BTK inhibitor pill that reaches the brain, for PCNSL that relapsed after methotrexate-based treatment.

What they found

What it means

Basis for a US accelerated-approval application; already approved in Japan.

Blood, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.